First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma
The antitumor activity of immunotherapy is strongly influenced by the presence of driver gene mutations/translocations. For this reason, knowledge of the predictive value of specific genetic alterations in relation to anti-PD(L)1 activity is highly useful for the clinical decision making process in...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/2/68 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850080675663708160 |
|---|---|
| author | Tommaso Martino De Pas Giuseppe Giaccone Chiara Catania Fabio Conforti Laura Pala Periklis Mitsakis Pierre-Yves Dietrich |
| author_facet | Tommaso Martino De Pas Giuseppe Giaccone Chiara Catania Fabio Conforti Laura Pala Periklis Mitsakis Pierre-Yves Dietrich |
| author_sort | Tommaso Martino De Pas |
| collection | DOAJ |
| description | The antitumor activity of immunotherapy is strongly influenced by the presence of driver gene mutations/translocations. For this reason, knowledge of the predictive value of specific genetic alterations in relation to anti-PD(L)1 activity is highly useful for the clinical decision making process in many solid tumors, particularly in Non-Small Cell Lung Cancer. Although data on the correlation between genetic alterations and response to immunotherapy are available in the majority of common cancers, data are lacking in the subset of patients with KIT-mutated Thymic Carcinoma (TC). As a consequence, although immunotherapy is a standard treatment for TC patients, the lack of this knowledge leads to uncertainty when proposing immunocheckpoint inhibitors in this subset of patients. Here we describe the first report of a patient with KIT-mutated TC who received the anti-PD1 agent pembrolizumab, which caused a sustained partial response. This case report of a sustained partial response achieved with pembrolizumab in a patient with KIT-mutated TC after progression to chemotherapy and imatinib may be supportive during clinical decision making for this extremely rare disease. |
| format | Article |
| id | doaj-art-45c5c9d36fb3406a91cbcb34b2f96cad |
| institution | DOAJ |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-45c5c9d36fb3406a91cbcb34b2f96cad2025-08-20T02:44:53ZengMDPI AGCurrent Oncology1198-00521718-77292025-01-013226810.3390/curroncol32020068First Report of Pembrolizumab Activity in KIT-Mutated Thymic CarcinomaTommaso Martino De Pas0Giuseppe Giaccone1Chiara Catania2Fabio Conforti3Laura Pala4Periklis Mitsakis5Pierre-Yves Dietrich6Division of Medical Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, ItalyDepartment of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10075, USADivision of Medical Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, ItalyDivision of Medical Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, ItalyDivision of Medical Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, ItalyNuclear Medicine, Hirslanden Clinique des Grangettes, 1224 Geneva, SwitzerlandMedical Oncology, Hirslanden Clinique des Grangettes, 1208 Geneva, SwitzerlandThe antitumor activity of immunotherapy is strongly influenced by the presence of driver gene mutations/translocations. For this reason, knowledge of the predictive value of specific genetic alterations in relation to anti-PD(L)1 activity is highly useful for the clinical decision making process in many solid tumors, particularly in Non-Small Cell Lung Cancer. Although data on the correlation between genetic alterations and response to immunotherapy are available in the majority of common cancers, data are lacking in the subset of patients with KIT-mutated Thymic Carcinoma (TC). As a consequence, although immunotherapy is a standard treatment for TC patients, the lack of this knowledge leads to uncertainty when proposing immunocheckpoint inhibitors in this subset of patients. Here we describe the first report of a patient with KIT-mutated TC who received the anti-PD1 agent pembrolizumab, which caused a sustained partial response. This case report of a sustained partial response achieved with pembrolizumab in a patient with KIT-mutated TC after progression to chemotherapy and imatinib may be supportive during clinical decision making for this extremely rare disease.https://www.mdpi.com/1718-7729/32/2/68thymic carcinomaimmunotherapyKIT mutation |
| spellingShingle | Tommaso Martino De Pas Giuseppe Giaccone Chiara Catania Fabio Conforti Laura Pala Periklis Mitsakis Pierre-Yves Dietrich First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma Current Oncology thymic carcinoma immunotherapy KIT mutation |
| title | First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma |
| title_full | First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma |
| title_fullStr | First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma |
| title_full_unstemmed | First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma |
| title_short | First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma |
| title_sort | first report of pembrolizumab activity in kit mutated thymic carcinoma |
| topic | thymic carcinoma immunotherapy KIT mutation |
| url | https://www.mdpi.com/1718-7729/32/2/68 |
| work_keys_str_mv | AT tommasomartinodepas firstreportofpembrolizumabactivityinkitmutatedthymiccarcinoma AT giuseppegiaccone firstreportofpembrolizumabactivityinkitmutatedthymiccarcinoma AT chiaracatania firstreportofpembrolizumabactivityinkitmutatedthymiccarcinoma AT fabioconforti firstreportofpembrolizumabactivityinkitmutatedthymiccarcinoma AT laurapala firstreportofpembrolizumabactivityinkitmutatedthymiccarcinoma AT periklismitsakis firstreportofpembrolizumabactivityinkitmutatedthymiccarcinoma AT pierreyvesdietrich firstreportofpembrolizumabactivityinkitmutatedthymiccarcinoma |